Autonomic Failure

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Autonomic Failure is an early-stage landscape with 0 programs across 1 company. The most active players are Theravance Biopharma.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

33/100

Attrition Rate

44/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Theravance Biopharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Terminated4 · 44%

Recruiting3 · 33%

Completed2 · 22%

Clinical Trials

Trial Activity

9 trials

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

Recruiting·VVanderbilt University Medical Center·Phase 1·NCT04620382·31 enrolled

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Recruiting·—·Phase 1·NCT04246437·40 enrolled

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

Recruiting·VVanderbilt University Medical Center·Phase 1·NCT02897063·34 enrolled

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Completed·TTheravance Biopharma·Phase 3·NCT03750552·195 enrolled

Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

Completed·VVanderbilt University Medical Center·Phase 2·NCT02784535·48 enrolled

Water and Sudafed in Autonomic Failure

Terminated·VVanderbilt University·Phase 1·NCT02149901·35 enrolled

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

Terminated·VVanderbilt University Medical Center·Phase 1·NCT02591173·7 enrolled

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Terminated·TTheravance Biopharma·Phase 3·NCT04095793·110 enrolled

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Terminated·TTheravance Biopharma·Phase 3·NCT03829657·203 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)